Denali Therapeutics (DNLI) to Release Earnings on Thursday

Key Points

• Denali Therapeutics is expected to release its Q2 2025 earnings on August 7, with analysts predicting a loss of ($0.73) per share.
• The company recently reported a ($0.78) EPS for the previous quarter, missing estimates and showing a year-over-year increase in losses.
• Institutional investors have strengthened their positions in Denali Therapeutics, with 92.92% of the stock currently owned by such investors.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Denali Therapeutics to post earnings of ($0.73) per share and revenue of $5.64 million for the quarter.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period in the prior year, the business posted ($0.68) earnings per share. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Denali Therapeutics Stock Down 2.8%

Shares of DNLI stock traded down $0.39 during trading hours on Friday, reaching $13.44. 1,762,097 shares of the company's stock were exchanged, compared to its average volume of 1,381,198. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The stock has a market capitalization of $1.95 billion, a P/E ratio of -5.03 and a beta of 1.36. The business has a fifty day moving average price of $14.20 and a 200-day moving average price of $15.90.

Insider Buying and Selling at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 495,282 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total transaction of $7,429,230.00. Following the completion of the sale, the chief executive officer directly owned 253,071 shares in the company, valued at $3,796,065. This represents a 66.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 12.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DNLI. Goldman Sachs Group Inc. increased its holdings in Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company's stock worth $22,732,000 after purchasing an additional 614,555 shares in the last quarter. Woodline Partners LP increased its holdings in Denali Therapeutics by 13.5% in the 1st quarter. Woodline Partners LP now owns 113,517 shares of the company's stock worth $1,543,000 after purchasing an additional 13,517 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Denali Therapeutics by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company's stock worth $1,210,000 after purchasing an additional 3,432 shares in the last quarter. Finally, Empowered Funds LLC increased its holdings in Denali Therapeutics by 11.0% in the 1st quarter. Empowered Funds LLC now owns 20,639 shares of the company's stock worth $281,000 after purchasing an additional 2,052 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have weighed in on DNLI. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Monday, July 28th. Robert W. Baird dropped their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Wedbush dropped their price target on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright lowered their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of "Buy" and an average target price of $33.85.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.